Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-10, Vol.30, p.v34 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | v34 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Yang, C. Iafolla, M.A. Dashner, S. Xu, W. Hansen, A.R. Bedard, P. Lheureux, S. Spreafico, A. Razak, A.A. Wu, H.-T. Shchegrova, S. Liu, Z.A. Ohashi, P.S. Torti, D. Louie, M. Sethi, H. Aleshin, A. Siu, L.L. Bratman, S. Pugh, T.J. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz239.024 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz239_024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdz239_024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1334-7712b759616008025d754a50cb432bdeb1950cbc13108f4d1b71e9442e2a04d93</originalsourceid><addsrcrecordid>eNotkEtPAjEUhbvQRER_gLu7hMVAX8PQJeIzIepC15O-wMpMZ9IWDfwMf7ElmNzk5CbnnJv7IXRD8IRgwabS-87raWsOlIkJpvwMDbCgrKhKxi_QZYxfGOOZoGKAfm9t7LutBe2C3jUyOb-BtGu7AHcvCxjplGUM0stmH10EmQf6YI3TyX1bUK5rZdjaAM5D7Bpn_tN9rrI-RRj1KY4hBSuTNfDj0ifEfKSxIDfZAL1tVcjBw66VCkZv4yt0vpZNtNf_OkQfD_fvy6di9fr4vFysCk0Y40VVEaqqUszIDOM5pqWpSi5LrBVnVBmriDgu2UzwfM0NURWxgnNqqcTcCDZE5NSrQxdjsOu6Dy4_s68Jro8g6xPI-gSyziDZH6eAbGI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yang, C. ; Iafolla, M.A. ; Dashner, S. ; Xu, W. ; Hansen, A.R. ; Bedard, P. ; Lheureux, S. ; Spreafico, A. ; Razak, A.A. ; Wu, H.-T. ; Shchegrova, S. ; Liu, Z.A. ; Ohashi, P.S. ; Torti, D. ; Louie, M. ; Sethi, H. ; Aleshin, A. ; Siu, L.L. ; Bratman, S. ; Pugh, T.J.</creator><creatorcontrib>Yang, C. ; Iafolla, M.A. ; Dashner, S. ; Xu, W. ; Hansen, A.R. ; Bedard, P. ; Lheureux, S. ; Spreafico, A. ; Razak, A.A. ; Wu, H.-T. ; Shchegrova, S. ; Liu, Z.A. ; Ohashi, P.S. ; Torti, D. ; Louie, M. ; Sethi, H. ; Aleshin, A. ; Siu, L.L. ; Bratman, S. ; Pugh, T.J.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdz239.024</identifier><language>eng</language><ispartof>Annals of oncology, 2019-10, Vol.30, p.v34</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1334-7712b759616008025d754a50cb432bdeb1950cbc13108f4d1b71e9442e2a04d93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Yang, C.</creatorcontrib><creatorcontrib>Iafolla, M.A.</creatorcontrib><creatorcontrib>Dashner, S.</creatorcontrib><creatorcontrib>Xu, W.</creatorcontrib><creatorcontrib>Hansen, A.R.</creatorcontrib><creatorcontrib>Bedard, P.</creatorcontrib><creatorcontrib>Lheureux, S.</creatorcontrib><creatorcontrib>Spreafico, A.</creatorcontrib><creatorcontrib>Razak, A.A.</creatorcontrib><creatorcontrib>Wu, H.-T.</creatorcontrib><creatorcontrib>Shchegrova, S.</creatorcontrib><creatorcontrib>Liu, Z.A.</creatorcontrib><creatorcontrib>Ohashi, P.S.</creatorcontrib><creatorcontrib>Torti, D.</creatorcontrib><creatorcontrib>Louie, M.</creatorcontrib><creatorcontrib>Sethi, H.</creatorcontrib><creatorcontrib>Aleshin, A.</creatorcontrib><creatorcontrib>Siu, L.L.</creatorcontrib><creatorcontrib>Bratman, S.</creatorcontrib><creatorcontrib>Pugh, T.J.</creatorcontrib><title>Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkEtPAjEUhbvQRER_gLu7hMVAX8PQJeIzIepC15O-wMpMZ9IWDfwMf7ElmNzk5CbnnJv7IXRD8IRgwabS-87raWsOlIkJpvwMDbCgrKhKxi_QZYxfGOOZoGKAfm9t7LutBe2C3jUyOb-BtGu7AHcvCxjplGUM0stmH10EmQf6YI3TyX1bUK5rZdjaAM5D7Bpn_tN9rrI-RRj1KY4hBSuTNfDj0ifEfKSxIDfZAL1tVcjBw66VCkZv4yt0vpZNtNf_OkQfD_fvy6di9fr4vFysCk0Y40VVEaqqUszIDOM5pqWpSi5LrBVnVBmriDgu2UzwfM0NURWxgnNqqcTcCDZE5NSrQxdjsOu6Dy4_s68Jro8g6xPI-gSyziDZH6eAbGI</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Yang, C.</creator><creator>Iafolla, M.A.</creator><creator>Dashner, S.</creator><creator>Xu, W.</creator><creator>Hansen, A.R.</creator><creator>Bedard, P.</creator><creator>Lheureux, S.</creator><creator>Spreafico, A.</creator><creator>Razak, A.A.</creator><creator>Wu, H.-T.</creator><creator>Shchegrova, S.</creator><creator>Liu, Z.A.</creator><creator>Ohashi, P.S.</creator><creator>Torti, D.</creator><creator>Louie, M.</creator><creator>Sethi, H.</creator><creator>Aleshin, A.</creator><creator>Siu, L.L.</creator><creator>Bratman, S.</creator><creator>Pugh, T.J.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201910</creationdate><title>Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)</title><author>Yang, C. ; Iafolla, M.A. ; Dashner, S. ; Xu, W. ; Hansen, A.R. ; Bedard, P. ; Lheureux, S. ; Spreafico, A. ; Razak, A.A. ; Wu, H.-T. ; Shchegrova, S. ; Liu, Z.A. ; Ohashi, P.S. ; Torti, D. ; Louie, M. ; Sethi, H. ; Aleshin, A. ; Siu, L.L. ; Bratman, S. ; Pugh, T.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1334-7712b759616008025d754a50cb432bdeb1950cbc13108f4d1b71e9442e2a04d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, C.</creatorcontrib><creatorcontrib>Iafolla, M.A.</creatorcontrib><creatorcontrib>Dashner, S.</creatorcontrib><creatorcontrib>Xu, W.</creatorcontrib><creatorcontrib>Hansen, A.R.</creatorcontrib><creatorcontrib>Bedard, P.</creatorcontrib><creatorcontrib>Lheureux, S.</creatorcontrib><creatorcontrib>Spreafico, A.</creatorcontrib><creatorcontrib>Razak, A.A.</creatorcontrib><creatorcontrib>Wu, H.-T.</creatorcontrib><creatorcontrib>Shchegrova, S.</creatorcontrib><creatorcontrib>Liu, Z.A.</creatorcontrib><creatorcontrib>Ohashi, P.S.</creatorcontrib><creatorcontrib>Torti, D.</creatorcontrib><creatorcontrib>Louie, M.</creatorcontrib><creatorcontrib>Sethi, H.</creatorcontrib><creatorcontrib>Aleshin, A.</creatorcontrib><creatorcontrib>Siu, L.L.</creatorcontrib><creatorcontrib>Bratman, S.</creatorcontrib><creatorcontrib>Pugh, T.J.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, C.</au><au>Iafolla, M.A.</au><au>Dashner, S.</au><au>Xu, W.</au><au>Hansen, A.R.</au><au>Bedard, P.</au><au>Lheureux, S.</au><au>Spreafico, A.</au><au>Razak, A.A.</au><au>Wu, H.-T.</au><au>Shchegrova, S.</au><au>Liu, Z.A.</au><au>Ohashi, P.S.</au><au>Torti, D.</au><au>Louie, M.</au><au>Sethi, H.</au><au>Aleshin, A.</au><au>Siu, L.L.</au><au>Bratman, S.</au><au>Pugh, T.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)</atitle><jtitle>Annals of oncology</jtitle><date>2019-10</date><risdate>2019</risdate><volume>30</volume><spage>v34</spage><pages>v34-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdz239.024</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-10, Vol.30, p.v34 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz239_024 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A50%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bespoke%20circulating%20tumor%20DNA%20(ctDNA)%20analysis%20as%20a%20predictive%20biomarker%20in%20solid%20tumor%20patients%20(pts)%20treated%20with%20single%20agent%20pembrolizumab%20(P)&rft.jtitle=Annals%20of%20oncology&rft.au=Yang,%20C.&rft.date=2019-10&rft.volume=30&rft.spage=v34&rft.pages=v34-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdz239.024&rft_dat=%3Ccrossref%3E10_1093_annonc_mdz239_024%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |